Epitalon (free base) and Epitalon acetate
Neither substance is a component of an FDA-approved drug. FDA's 2026 evaluation concluded that the evidence weighed against adding either substance to the 503A Bulks List.
Current sourceEpitalon
What FDA's review found—and why pineal-extract studies are not Epitalon trials
Epitalon (also spelled Epithalon) is a synthetic four-amino-acid peptide promoted online for sleep and longevity. It is not an FDA-approved drug. FDA's 2026 review distinguished Epitalon from Epithalamin, a pineal-gland polypeptide extract, and found inadequate human evidence for the proposed insomnia use and insufficient human safety data.
Editorial status
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .
It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
Products sold as Epitalon or Epithalon
Online availability does not establish FDA approval, pharmaceutical identity, or evidence of safety and effectiveness. FDA identified inconsistent naming and characterization among nominated materials.
Current sourceClaim-by-claim evidence map
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
Epitalon and Epithalamin are not the same substance.
- Population
- FDA chemistry and clinical review of Epitalon-related bulk drug substances.
- Finding
- FDA describes Epitalon as a synthetic tetrapeptide and Epithalamin as a polypeptide complex extracted from pineal glands; evidence for the extract cannot be assumed to establish effects of the tetrapeptide.
- Limits
- The FDA document is a regulatory evidence review, not a clinical trial, but the identity distinction is essential when interpreting older literature.
Human evidence for Epitalon in insomnia is inadequate.
- Population
- Studies and abstracts located by FDA for its proposed insomnia-use evaluation.
- Finding
- FDA concluded that the available information did not support effectiveness for insomnia and noted substantial limitations in the identified reports.
- Limits
- Absence of adequate evidence is not proof of no effect; it means benefit has not been established in well-controlled human trials.
Human safety for Epitalon remains insufficiently characterized.
- Population
- Publicly available human reports and safety databases reviewed by FDA.
- Finding
- FDA reported no adequate clinical safety data for Epitalon free base or acetate and identified potential immunogenicity concerns related to aggregation and peptide impurities, especially for injection.
- Limits
- These are potential and unknown risks, not quantified event rates from a controlled trial.
What this evidence does not answer
- No adequate randomized human trial establishes Epitalon's effect on insomnia, lifespan, healthspan, cognition, or telomere-related clinical outcomes.
- Results from Epithalamin, animal experiments, cell studies, or uncontrolled biomarker reports cannot establish a clinical benefit for synthetic Epitalon.
- Product identity, salt form, purity, sterility, aggregation, and peptide-related impurities may differ among products sold under the same common name.
Useful information to organize between visits
- The exact product name, stated chemical form, manufacturer, and lot—not only the word Epitalon
- Any certificate of analysis and whether it addresses identity, purity, sterility, endotoxin, and aggregation
- All symptoms with timing, severity, duration, and the product lot involved
- Other medicines, supplements, or experimental products used at the same time
- Questions to take to a licensed clinician or pharmacist rather than relying on seller claims
Questions to bring to a clinician or pharmacist
- 1.What evidence applies to Epitalon itself rather than the different pineal extract Epithalamin?
- 2.Could my symptoms, medicines, or health history make an unapproved peptide particularly risky?
- 3.How should a suspected adverse event or product-quality concern be documented and reported?
- 4.What approved options have evidence for the symptom or condition I am trying to address?
Primary sources
- FDA Evaluation of Epitalon-Related Bulk Drug SubstancesU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
- July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting materialsU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
- Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety RisksU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
Turn scattered notes into a useful treatment history
Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.
Start tracking free